<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04013243</url>
  </required_header>
  <id_info>
    <org_study_id>B-1902/523-007</org_study_id>
    <nct_id>NCT04013243</nct_id>
  </id_info>
  <brief_title>Effect of Magnesium on Dose of Rocuronium for Deep Neuromuscular Blockade</brief_title>
  <official_title>Effect of Magnesium on Maintenance Dose of Rocuronium for Deep Neuromuscular Blockade During Robotic Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is well known that magnesium enhances the effect of neuromuscular blocking agents such as
      rocuronium. However, it is not known how much magnesium can reduce neuromuscular blocking
      agents in maintaining deep neuromuscular blockade. Through this study, the investigators will
      quantitatively analyze the rocuronium saving effect of magnesium.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is well known that magnesium potentiate the effect of neuromuscular blocking agents. It
      prolonged the duration of rocuronium and reduces the onset time of rocuronium. Magnesium acts
      on motor end plate, where magnesium reduces the release of prejunctional acetylcholine,
      thereby decreasing the muscle membrane excitability. However, the quantitative rocuronium
      saving effect of magnesium is not clear. This study's hypothesis is that magnesium would
      reduce the amount of rocuronium. And the investigators want to evaluate how much magnesium
      can reduce the amount of rocuronium. Secondary outcome is the effects of magnesium on
      recovery time, postoperative pain, nausea and vomiting.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2019</start_date>
  <completion_date type="Anticipated">July 19, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 5, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rocuronium amount</measure>
    <time_frame>perioperative - until 48hours</time_frame>
    <description>total rocuronium/weight/infusion time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>recovery time</measure>
    <time_frame>perioperative - until 48hours</time_frame>
    <description>time from sugammadex injection to Train-of-four ratio 0.9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative pain</measure>
    <time_frame>at postoperative 30minutes, 6hours, 24hours</time_frame>
    <description>11 point Numerical Rating Scale; 0 (no pain) to 10 (worst imaginable pain), rescue medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative nausea and vomiting</measure>
    <time_frame>at postoperative 30minutes, 6hours, 24hours</time_frame>
    <description>Numerical Rating Scale(0-10), rescue medication</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Magnesium Sulfate Causing Adverse Effects in Therapeutic Use</condition>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>Magnesium Sulfate group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>magnesium sulphate 50mg/kg in normal saline 50ml infusion for 10minutes for loading dose followed by 15mg/kg/hr for continuous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline 50ml infusion for loading dose followed by continuous infusion for same dose of magnesium.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Sulfate</intervention_name>
    <description>magnesium sulphate 50mg/kg in normal saline 50ml infusion for 10minutes for loading dose followed by 15mg/kg/hr for continuous infusion</description>
    <arm_group_label>Magnesium Sulfate group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal Saline 50ml infusion for loading dose followed by continuous infusion for same dose of magnesium.</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who undergo elective robot assisted radical prostatectomy, between 20 and 80
             years with a American Society of Anesthesiologists physical status classification of I
             or II

        Exclusion Criteria:

          -  Conduction abnormalities in preoperative EKG such as Atrioventricular block, sinus
             pause

          -  Glomerular filtration rate &lt;60ml/min/1.73m2

          -  Allergy to rocuronium, sugammadex, magnesium

          -  Medications that interfered with muscle activity

          -  Neuromuscular disease

          -  Hypermagnesemia
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ah-young Oh, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ji-won Han, fellow</last_name>
    <phone>82-10-3447-1988</phone>
    <email>hanjiwon@snubh.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ah-young Oh, professor</last_name>
    <phone>82-31-787-7506</phone>
    <email>oay1@snubh.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiwon Han, fellow</last_name>
      <phone>82-10-3447-1988</phone>
      <email>yesuroon@naver.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Queiroz Rangel Micuci AJ, Ver√ßosa N, Filho PAG, de Boer HD, Barbosa DD, Cavalcanti IL. Effect of pretreatment with magnesium sulphate on the duration of intense and deep neuromuscular blockade with rocuronium: A randomised controlled trial. Eur J Anaesthesiol. 2019 Jul;36(7):502-508. doi: 10.1097/EJA.0000000000001003.</citation>
    <PMID>30985540</PMID>
  </results_reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 28, 2019</study_first_submitted>
  <study_first_submitted_qc>July 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2019</study_first_posted>
  <last_update_submitted>July 8, 2019</last_update_submitted>
  <last_update_submitted_qc>July 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>JiWon Han</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Magnesium</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

